Redeye Feed

2025-08-22 17:42:00 Medivir Q2 2025 - Awaiting Phase IIb

2025-08-22 12:57:00 Initiator Pharma Q2 - Financed to explore vulvodynia

2025-08-22 10:47:00 Ascelia Pharma - Just about to submit Orviglance for US approval

2025-08-22 10:46:00 Better Collective - Reiterated guidance supports positive view

2025-08-22 10:45:00 Oncopeptides Q2 2025 - Funded Until Profitability

2025-08-22 10:44:00 Surgical Science Q2 2025 - Expect continued volatility

2025-08-22 10:43:00 Catella - Standing firm, moving forward

2025-08-22 10:42:00 Mendus Q2 2025 - Nearing phase III-readiness

2025-08-21 11:46:00 OncoZenge Q2 - Financed for fully European phase III study

2025-08-21 10:43:00 Starbreeze - Effect from “publishing switch” in Q3

2025-08-21 10:42:00 Alzinova Q2 - Progress toward phase II study

2025-08-21 10:41:00 Teneo AI - Building pipeline

2025-08-21 10:40:00 SynAct Q2 2025 - Improved Cash and New PMR Programme

2025-08-21 10:39:00 Cheffelo - Momentum remains on the menu

2025-08-21 10:38:00 Paxman Q2 - Nothing spectacular, but in the right direction

2025-08-20 10:41:00 Formpipe - Public going private

2025-08-20 10:40:00 Scibase Q2 - Advancing on the right track

2025-08-20 10:39:00 OssDsign Q2 - Strong sales but higher costs ahead

2025-08-20 10:38:00 Kontigo Care - Q2 2025 – Turning the corner, growth ahead

2025-08-19 08:48:00 Xspray Pharma Q2 2025 - Case defining months ahead

2025-08-19 08:47:00 Nitro Games - Rising Uncertainty

2025-08-18 10:08:00 EG7 - Solid launch of Palia overshadowed by negative FX

2025-08-18 10:07:00 Embracer - Reset of expectations

2025-08-18 10:06:00 Verve Group - Platform integration and FX headwinds pressure 2025 results

2025-08-18 10:05:00 Redeye Initiates Coverage of Relais Group

2025-08-18 10:04:00 Xplora - Doro drives growth, but all eyes are on conversion rates

2025-08-18 10:03:00 Safello - Navigating a critical crossroads

2025-08-15 09:22:00 Transtema - Potential in power

2025-08-15 09:21:00 Bredband2 Q2 Review - Positive revisions

2025-08-14 16:21:00 Scandinavian ChemoTech - Growth tailwinds

2025-08-13 11:48:00 Moberg Pharma - Terclara is the market leader in both Sweden and Norway

2025-08-13 11:47:00 Genovis Q2 2025 - Undramatic report but recent developments are case supporting

2025-08-12 12:14:00 RaySearch Q2 - Gearing up for more record quarters

2025-08-08 15:32:00 G5 Entertainment - New game releases coming closer

2025-08-08 15:31:00 BeammWave - Tune in for the tape-out

2025-08-08 15:30:00 Optomed Q2 - Soft Q2 sales raises the stakes for H2 recovery

2025-08-06 17:41:00 W5 Solutions - Strong outlook for H2 2025

2025-08-06 17:39:00 Freemelt - Gearing up to the next level

2025-08-01 15:59:00 Magle Chemoswed Q2 - Delays weigh down the quarter’s results

2025-07-28 12:11:00 Modelon - Solid foundation amid FX and market headwinds

2025-07-28 12:10:00 Physitrack - Turning point for profitability

2025-07-28 12:07:00 OXE Marine - Solid execution

2025-07-28 12:06:00 Gapwaves - Long-term growth narrative becomes increasingly compelling

2025-07-28 12:05:00 Polygiene Group - Q2 Review – Temporary Setback

2025-07-25 11:36:00 NextCell Pharma Q3 2024/2025 - Largely as expected

2025-07-25 11:35:00 Eniro Group - Cutting costs

2025-07-23 14:05:00 MedCap Q2 2025 - The rise, fall, and rise again

2025-07-23 11:38:00 Devyser Q2 - Profitable from here on

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Redeye

Prenumeration

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden